USA— In the latest report by PatientView, which assesses the reputation of pharmaceutical companies based on feedback from over 2,200 patient groups worldwide, Roche, ViiV Healthcare, and Horizon Therapeutics emerged as the top three most reputable pharmas in 2022.
Notably, Pfizer, which had previously secured a top-ranking position, fell out of the top three.
The report is divided into two sections. The first section ranks the pharmas based on responses from patient groups familiar with the companies but not directly involved with them.
Roche, a leading player in oncology, claimed the first position, followed by ViiV Healthcare, specializing in HIV/AIDS treatments, in second place, and rare disease drugmaker Horizon Therapeutics in third place.
The second section focuses on responses from patient groups that work directly with the pharmas being ranked. This section accounted for a significant 88% of all respondents.
In this ranking, ViiV Healthcare secured the top spot, continuing its trend from 2021, with Horizon Therapeutics in second place and Roche in third place.
In 2021, ViiV Healthcare held the leading position, with Pfizer in second place and Roche in third place. However, Pfizer’s previous success, largely attributed to its COVID-19 vaccine, seems to be fading as it slipped from the top three positions.
The report also highlighted the significant reputation advancements of three companies: Vertex, a cystic fibrosis drug maker, Servier from France, and U.S. Big Pharma Merck.
These three companies experienced the most substantial improvement in their rankings compared to the previous year, with Vertex climbing 14 places, Servier rising by 12, and Merck moving up by nine spots, as acknowledged by patient groups that collaborate with these companies.
Although the pharmaceutical industry garnered positive recognition due to its response to the COVID-19 pandemic in 2020 and 2021, PatientView’s report suggests that the euphoria may be waning.
In 2020, 50% of respondents rated the reputation of pharmas as “excellent” or “good,” and that figure increased to 59% in 2021. However, in the most recent report, the percentage only slightly rose to 60%.
The report also shed light on a concerning aspect regarding access to medicines.
Only 32% of patient groups regarded pharma as “excellent” or “good” in terms of improving access to medicines, particularly with regards to affordability and distribution in underprivileged countries.
Over half of the respondents (52%) rated pharma as “fair” or “poor” in this regard, with the sentiment being most prevalent in African countries.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
